A Compassionate Use (CU) Program of Odronextamab
Sponsor
Regeneron Pharmaceuticals (Industry)
Overall Status
Available
CT.gov ID
NCT05619367
Collaborator
(none)
Study Details
Study Description
Brief Summary
Provide compassionate use of odronextamab
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Regeneron Pharmaceuticals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT05619367
Other Study ID Numbers:
- R1979-Odronextamab
First Posted:
Nov 16, 2022
Last Update Posted:
Nov 16, 2022
Last Verified:
Nov 1, 2022